Hongshang Chang

Title: Innovations of Hongshang Chang in Vaccine Development

Introduction

Hongshang Chang is a notable inventor based in Qingdao, China. He has made significant contributions to the field of vaccine development, particularly in response to the challenges posed by novel coronavirus pneumonia. His innovative approach has led to the creation of a unique vaccine strain that holds promise for both human and animal health.

Latest Patents

Hongshang Chang holds a patent for a paramyxovirus vaccine strain specifically designed for novel coronavirus pneumonia. The patent outlines a method that involves the recombination of N and F genes from Newcastle disease virus type VII with P, M, H, and L genes from Canine distemper virus. This innovative method allows for the insertion of the S1 gene of the novel coronavirus, resulting in a recombinant vector that can effectively express the S1 protein. The vaccine strain is designed to induce antibody production and stimulate mucosal immunity, making it suitable for administration via nasal spray. This approach not only saves time and reduces costs but also enhances the practicality of vaccine production.

Career Highlights

Hongshang Chang is associated with Qingdao Harwars Biology Group Ltd., where he continues to advance his research in vaccine technology. His work has been instrumental in developing solutions that address urgent health challenges, particularly in the context of viral infections.

Collaborations

He collaborates with esteemed colleagues such as Mingyi Li and Gang Liu, who contribute to the research and development efforts at Qingdao Harwars Biology Group Ltd. Their combined expertise fosters an environment of innovation and progress in the field of biotechnology.

Conclusion

Hongshang Chang's contributions to vaccine development exemplify the impact of innovative thinking in addressing global health issues. His patented methods and collaborative efforts position him as a key figure in the ongoing fight against infectious diseases.